Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, progno...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.857573/full |
| _version_ | 1828403069577068544 |
|---|---|
| author | Denise Battaglini Denise Battaglini Denise Battaglini Miquéias Lopes-Pacheco Hugo C. Castro-Faria-Neto Paolo Pelosi Paolo Pelosi Patricia R. M. Rocco Patricia R. M. Rocco Patricia R. M. Rocco |
| author_facet | Denise Battaglini Denise Battaglini Denise Battaglini Miquéias Lopes-Pacheco Hugo C. Castro-Faria-Neto Paolo Pelosi Paolo Pelosi Patricia R. M. Rocco Patricia R. M. Rocco Patricia R. M. Rocco |
| author_sort | Denise Battaglini |
| collection | DOAJ |
| description | Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19. |
| first_indexed | 2024-12-10T10:11:38Z |
| format | Article |
| id | doaj.art-a8066f371ec744b78cca68cd2714a107 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T10:11:38Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a8066f371ec744b78cca68cd2714a1072022-12-22T01:53:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-04-011310.3389/fimmu.2022.857573857573Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19Denise Battaglini0Denise Battaglini1Denise Battaglini2Miquéias Lopes-Pacheco3Hugo C. Castro-Faria-Neto4Paolo Pelosi5Paolo Pelosi6Patricia R. M. Rocco7Patricia R. M. Rocco8Patricia R. M. Rocco9Anesthesia and Intensive Care, San Martino Policlinico Hospital, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) for Oncology and Neuroscience, Genoa, ItalyDepartment of Surgical Science and Integrated Diagnostics (DISC), University of Genoa, Genoa, ItalyDepartment of Medicine, University of Barcelona, Barcelona, SpainLaboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilLaboratory of Immunopharmacology, Oswaldo Cruz Institute - Fiocruz, Rio de Janeiro, BrazilAnesthesia and Intensive Care, San Martino Policlinico Hospital, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) for Oncology and Neuroscience, Genoa, ItalyDepartment of Surgical Science and Integrated Diagnostics (DISC), University of Genoa, Genoa, ItalyLaboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, BrazilCOVID-19 Virus Network from Brazilian Council for Scientific and Technological Development, Brasília, BrazilCOVID-19 Virus Network from Foundation Carlos Chagas Filho Research Support of the State of Rio de Janeiro, Rio de Janeiro, BrazilSevere acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19.https://www.frontiersin.org/articles/10.3389/fimmu.2022.857573/fullbiomarkersCOVID-19inflammationmetabolomicsproteomics |
| spellingShingle | Denise Battaglini Denise Battaglini Denise Battaglini Miquéias Lopes-Pacheco Hugo C. Castro-Faria-Neto Paolo Pelosi Paolo Pelosi Patricia R. M. Rocco Patricia R. M. Rocco Patricia R. M. Rocco Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 Frontiers in Immunology biomarkers COVID-19 inflammation metabolomics proteomics |
| title | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
| title_full | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
| title_fullStr | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
| title_full_unstemmed | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
| title_short | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
| title_sort | laboratory biomarkers for diagnosis and prognosis in covid 19 |
| topic | biomarkers COVID-19 inflammation metabolomics proteomics |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.857573/full |
| work_keys_str_mv | AT denisebattaglini laboratorybiomarkersfordiagnosisandprognosisincovid19 AT denisebattaglini laboratorybiomarkersfordiagnosisandprognosisincovid19 AT denisebattaglini laboratorybiomarkersfordiagnosisandprognosisincovid19 AT miqueiaslopespacheco laboratorybiomarkersfordiagnosisandprognosisincovid19 AT hugoccastrofarianeto laboratorybiomarkersfordiagnosisandprognosisincovid19 AT paolopelosi laboratorybiomarkersfordiagnosisandprognosisincovid19 AT paolopelosi laboratorybiomarkersfordiagnosisandprognosisincovid19 AT patriciarmrocco laboratorybiomarkersfordiagnosisandprognosisincovid19 AT patriciarmrocco laboratorybiomarkersfordiagnosisandprognosisincovid19 AT patriciarmrocco laboratorybiomarkersfordiagnosisandprognosisincovid19 |